138 related articles for article (PubMed ID: 11939408)
1. Novel mdm2 splice variants identified in pediatric rhabdomyosarcoma tumors and cell lines.
Bartel F; Taylor AC; Taubert H; Harris LC
Oncol Res; 2001; 12(11-12):451-7. PubMed ID: 11939408
[TBL] [Abstract][Full Text] [Related]
2. P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines.
Taylor AC; Shu L; Danks MK; Poquette CA; Shetty S; Thayer MJ; Houghton PJ; Harris LC
Med Pediatr Oncol; 2000 Aug; 35(2):96-103. PubMed ID: 10918230
[TBL] [Abstract][Full Text] [Related]
3. Stress-induced isoforms of MDM2 and MDM4 correlate with high-grade disease and an altered splicing network in pediatric rhabdomyosarcoma.
Jacob AG; O'Brien D; Singh RK; Comiskey DF; Littleton RM; Mohammad F; Gladman JT; Widmann MC; Jeyaraj SC; Bolinger C; Anderson JR; Barkauskas DA; Boris-Lawrie K; Chandler DS
Neoplasia; 2013 Sep; 15(9):1049-63. PubMed ID: 24027430
[TBL] [Abstract][Full Text] [Related]
4. A novel mouse model of rhabdomyosarcoma underscores the dichotomy of MDM2-ALT1 function in vivo.
Comiskey DF; Jacob AG; Sanford BL; Montes M; Goodwin AK; Steiner H; Matsa E; Tapia-Santos AS; Bebee TW; Grieves J; La Perle K; Boyaka P; Chandler DS
Oncogene; 2018 Jan; 37(1):95-106. PubMed ID: 28892044
[TBL] [Abstract][Full Text] [Related]
5. Alternative and aberrant splicing of MDM2 mRNA in human cancer.
Bartel F; Taubert H; Harris LC
Cancer Cell; 2002 Jul; 2(1):9-15. PubMed ID: 12150820
[TBL] [Abstract][Full Text] [Related]
6. The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein.
Keleti J; Quezado MM; Abaza MM; Raffeld M; Tsokos M
Am J Pathol; 1996 Jul; 149(1):143-51. PubMed ID: 8686737
[TBL] [Abstract][Full Text] [Related]
7. Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms.
Matsumoto R; Tada M; Nozaki M; Zhang CL; Sawamura Y; Abe H
Cancer Res; 1998 Feb; 58(4):609-13. PubMed ID: 9485008
[TBL] [Abstract][Full Text] [Related]
8. Expression of alternatively spliced mdm2 transcripts correlates with stabilized wild-type p53 protein in human glioblastoma cells.
Kraus A; Neff F; Behn M; Schuermann M; Muenkel K; Schlegel J
Int J Cancer; 1999 Mar; 80(6):930-4. PubMed ID: 10074928
[TBL] [Abstract][Full Text] [Related]
9. Expression of alternatively-spliced MDM2 transcripts in giant cell tumours of bone.
Evdokiou A; Atkins GJ; Bouralexis S; Hay S; Raggatt LJ; Cowled PA; Graves SE; Clayer M; Findlay DM
Int J Oncol; 2001 Sep; 19(3):625-32. PubMed ID: 11494046
[TBL] [Abstract][Full Text] [Related]
10. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer.
Lukas J; Gao DQ; Keshmeshian M; Wen WH; Tsao-Wei D; Rosenberg S; Press MF
Cancer Res; 2001 Apr; 61(7):3212-9. PubMed ID: 11306511
[TBL] [Abstract][Full Text] [Related]
11. Amplification of the MDM2 gene, but not expression of splice variants of MDM2 MRNA, is associated with prognosis in soft tissue sarcoma.
Bartel F; Meye A; Würl P; Kappler M; Bache M; Lautenschläger C; Grünbaum U; Schmidt H; Taubert H
Int J Cancer; 2001 May; 95(3):168-75. PubMed ID: 11307150
[TBL] [Abstract][Full Text] [Related]
12. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer.
Sigalas I; Calvert AH; Anderson JJ; Neal DE; Lunec J
Nat Med; 1996 Aug; 2(8):912-7. PubMed ID: 8705862
[TBL] [Abstract][Full Text] [Related]
13. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status.
Flørenes VA; Maelandsmo GM; Forus A; Andreassen A; Myklebost O; Fodstad O
J Natl Cancer Inst; 1994 Sep; 86(17):1297-302. PubMed ID: 8064888
[TBL] [Abstract][Full Text] [Related]
14. Infrequency of MDM2 gene amplification in pediatric solid tumors and lack of association with p53 mutations in adult squamous cell carcinomas.
Waber PG; Chen J; Nisen PD
Cancer Res; 1993 Dec; 53(24):6028-30. PubMed ID: 8261417
[TBL] [Abstract][Full Text] [Related]
15. Tumor promotion by Mdm2 splice variants unable to bind p53.
Fridman JS; Hernando E; Hemann MT; de Stanchina E; Cordon-Cardo C; Lowe SW
Cancer Res; 2003 Sep; 63(18):5703-6. PubMed ID: 14522887
[TBL] [Abstract][Full Text] [Related]
16. Amplification of MDM2 inhibits MyoD-mediated myogenesis.
Fiddler TA; Smith L; Tapscott SJ; Thayer MJ
Mol Cell Biol; 1996 Sep; 16(9):5048-57. PubMed ID: 8756663
[TBL] [Abstract][Full Text] [Related]
17. The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas.
Calogero A; Arcella A; De Gregorio G; Porcellini A; Mercola D; Liu C; Lombari V; Zani M; Giannini G; Gagliardi FM; Caruso R; Gulino A; Frati L; Ragona G
Clin Cancer Res; 2001 Sep; 7(9):2788-96. PubMed ID: 11555594
[TBL] [Abstract][Full Text] [Related]
18. Analysis of p53 mutational events and MDM2 amplification in canine soft-tissue sarcomas.
Nasir L; Rutteman GR; Reid SW; Schulze C; Argyle DJ
Cancer Lett; 2001 Dec; 174(1):83-9. PubMed ID: 11675155
[TBL] [Abstract][Full Text] [Related]
19. Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification.
Habuchi T; Kinoshita H; Yamada H; Kakehi Y; Ogawa O; Wu WJ; Takahashi R; Sugiyama T; Yoshida O
J Natl Cancer Inst; 1994 Sep; 86(17):1331-5. PubMed ID: 8064891
[TBL] [Abstract][Full Text] [Related]
20. The MDM2 oncoprotein promotes apoptosis in p53-deficient human medullary thyroid carcinoma cells.
Dilla T; Velasco JA; Medina DL; González-Palacios JF; Santisteban P
Endocrinology; 2000 Jan; 141(1):420-9. PubMed ID: 10614665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
